The expression of lncRNAs CASC2, NEAT1, LINC00299 in breast cancer tissues and their relationship with the XBP1 splicing rate in Iranian patients during 2014-2019: A cross-sectional study.
XBP1
breast neoplasms
gene expression
long noncoding RNA
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
04
04
2023
revised:
29
07
2023
accepted:
30
08
2023
medline:
14
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Breast cancer is a leading cause of incidence and mortality in women globally. Identifying new molecular markers can aid in cancer diagnosis, targeted therapy, and treatment monitoring. This study aimed to measure the expression of the X-box binding protein 1 (XBP1) gene, an index of the unfolded protein response (UPR), and long noncoding RNAs (lncRNAs), including Nuclear Enriched Abundant Transcript 1 (NEAT1), Cancer Susceptibility Candidate 2 (CASC2), and Long Intergenic Nonprotein Coding RNA 299 (LINC00299), as possible regulators of the UPR pathway. Total RNA was extracted from 40 samples of breast tumor tissues and their respective controls. The expression level of lncRNAs CASC2, NEAT1, and LINC00299 was quantified using reverse transcription-polymerase chain reaction (RT-PCR). The ratio of the spliced form of XBP1 to its unspliced form (XBP1u) was determined by PCR and electrophoresis. The results showed a 2.8-fold increase in the ratio of XBP1s/u in breast cancer tissues compared to adjacent nonmalignant samples ( Based on the association between the expression of lncRNAs CASC2, LINC00299, and NEAT1 and the XBP1s/u ratio, these lncRNAs could be potential regulators of the UPR pathway. Also, CASC2 and NEAT1 genes could be suggested as suitable biomarkers to distinguish cancerous tissue from noncancerous breast tissue due to their significant increase in expression in cancerous samples compared to adjacent noncancerous.
Sections du résumé
Background and Aims
UNASSIGNED
Breast cancer is a leading cause of incidence and mortality in women globally. Identifying new molecular markers can aid in cancer diagnosis, targeted therapy, and treatment monitoring. This study aimed to measure the expression of the X-box binding protein 1 (XBP1) gene, an index of the unfolded protein response (UPR), and long noncoding RNAs (lncRNAs), including Nuclear Enriched Abundant Transcript 1 (NEAT1), Cancer Susceptibility Candidate 2 (CASC2), and Long Intergenic Nonprotein Coding RNA 299 (LINC00299), as possible regulators of the UPR pathway.
Methods
UNASSIGNED
Total RNA was extracted from 40 samples of breast tumor tissues and their respective controls. The expression level of lncRNAs CASC2, NEAT1, and LINC00299 was quantified using reverse transcription-polymerase chain reaction (RT-PCR). The ratio of the spliced form of XBP1 to its unspliced form (XBP1u) was determined by PCR and electrophoresis.
Results
UNASSIGNED
The results showed a 2.8-fold increase in the ratio of XBP1s/u in breast cancer tissues compared to adjacent nonmalignant samples (
Conclusions
UNASSIGNED
Based on the association between the expression of lncRNAs CASC2, LINC00299, and NEAT1 and the XBP1s/u ratio, these lncRNAs could be potential regulators of the UPR pathway. Also, CASC2 and NEAT1 genes could be suggested as suitable biomarkers to distinguish cancerous tissue from noncancerous breast tissue due to their significant increase in expression in cancerous samples compared to adjacent noncancerous.
Identifiants
pubmed: 37706018
doi: 10.1002/hsr2.1552
pii: HSR21552
pmc: PMC10495808
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1552Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819843889
pubmed: 30983509
Int J Mol Sci. 2015 Dec 02;16(12):28635-46
pubmed: 26633383
Heart Vessels. 2019 Aug;34(8):1370-1380
pubmed: 30734057
Mol Cancer. 2017 Jul 17;16(1):123
pubmed: 28716020
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2008 Jul 1;123(1):85-8
pubmed: 18386815
Cancers (Basel). 2019 Nov 16;11(11):
pubmed: 31744046
Biomed Pharmacother. 2020 Jul;127:110069
pubmed: 32294597
Oncotarget. 2017 Mar 14;8(11):18145-18153
pubmed: 28199978
J Hematol Oncol. 2020 Dec 2;13(1):163
pubmed: 33267910
Dis Markers. 2017;2017:7243968
pubmed: 28634418
Cell Cycle. 2021 Jul;20(13):1295-1307
pubmed: 34125645
Life Sci. 2021 Jan 1;264:118665
pubmed: 33127516
Biochem Biophys Res Commun. 2017 Jan 22;482(4):828-834
pubmed: 27888106
Int J Cancer. 2017 Jun 15;140(12):2785-2791
pubmed: 28295289
Health Sci Rep. 2023 Sep 11;6(9):e1552
pubmed: 37706018
Panminerva Med. 2022 Mar;64(1):38-47
pubmed: 32700888
Crit Rev Oncol Hematol. 2017 Mar;111:31-38
pubmed: 28259293
Am J Transl Res. 2016 Aug 15;8(8):3522-9
pubmed: 27648142
Cell Biosci. 2020 Mar 23;10:44
pubmed: 32211149
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Genes Dis. 2018 May 12;5(2):77-106
pubmed: 30258937